May 14, 2026 10:55AM
May 14, 2026 10:55AM
Jan 16, 2026 11:18AM
Dec 15, 2025 10:54AM
Dec 11, 2025 09:14AM
Sep 24, 2024 09:15AM
Aug 4, 2023 09:34AM Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter Research Solutions (RSSS)
Jan 20, 2022 07:30AM
Nov 10, 2021 04:10PM
Nov 8, 2021 07:30AM
Sep 20, 2021 07:00AM
Sep 15, 2021 07:08AM
Sep 15, 2021 07:00AM
Sep 13, 2021 07:00AM GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies
Sep 9, 2021 07:00AM
Sep 8, 2021 12:28PM
Aug 23, 2021 07:00AM
Aug 13, 2021 07:30AM
Aug 6, 2021 08:00AM
Aug 3, 2021 07:00AM
Jul 28, 2021 08:02AM GT Biopharma (GTBP) Receives $16M of Warrant Exercise Proceeds
Jul 28, 2021 08:00AM
Jul 7, 2021 08:00AM
Jun 23, 2021 08:00AM
May 18, 2021 09:50AM
May 17, 2021 06:54PM
May 12, 2021 07:07AM
May 12, 2021 07:00AM GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates
Apr 26, 2021 07:00AM
Apr 19, 2021 07:00AM
Apr 12, 2021 08:00AM
Apr 8, 2021 08:01AM
Apr 8, 2021 08:00AM
Mar 29, 2021 07:00AM
Mar 17, 2021 08:06AM GT Biopharma (GTBP) Announces Updated Interim GTB-3550 Trike Clinical Trial Results
Mar 17, 2021 08:00AM
Mar 10, 2021 08:00AM
Mar 8, 2021 08:36AM
Mar 8, 2021 08:30AM
Mar 4, 2021 08:30AM
Feb 18, 2021 08:00AM
Feb 11, 2021 08:00AM GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market
Jan 19, 2021 09:00AM
Jan 12, 2021 10:00AM
Jan 4, 2021 09:45AM
Dec 28, 2020 09:35AM
Dec 21, 2020 11:00AM
Dec 17, 2020 09:15AM
Dec 14, 2020 09:05AM GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market
Jan 21, 2020 08:45AM

1,155,679 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All